Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda Completes Divestment of Consumer Healthcare Unit to Blackstone
April 1, 2021
- Eisai/MSD File Lenvima-Keytruda Pair in Japan, Seeking 1st Nod for RCC
April 1, 2021
- Opdivo Filed as Adjuvant for Resected Urothelial Cancer in Japan
April 1, 2021
- Daiichi Sankyo to Terminates Vaccine Business Alliance with Sanofi in Japan
April 1, 2021
- Rohto to Invest in Kobe University Spin-Off to Develop Bio-Foundry
April 1, 2021
- GHIT Fund to Invest 2.3 Billion Yen in 10 Projects for Malaria, TB, Tropical Diseases
April 1, 2021
- Fujifilm Reorganizes Healthcare Biz Focusing on Biologics CDMO, Drug Development Support
April 1, 2021
- Astellas Integrates Audentes, Sets Up New In-House Unit for Gene Therapy
April 1, 2021
- Celgene Files Its 2nd CAR-T Therapy Ide-Cel in Japan: BMS
April 1, 2021
- Japan Trials Get Underway for AstraZeneca’s COVID-19 Antibody Therapy
April 1, 2021
- Lenvima/Keytruda Combo Accepted for EU Review for RCC, Endometrial Cancer
March 31, 2021
- Sumitovant Gets Entire Stake in Urovant: Sumitomo Dainippon
March 31, 2021
- Otsuka Partner Akebia Files HIF-PH Inhibitor Vadadustat in US
March 31, 2021
- JCR’s MPS I Drug Earns Orphan Status in Europe
March 31, 2021
- Nafamostat Inhalation Drug Now in Clinic for COVID-19: Daiichi Sankyo
March 31, 2021
- Xospata Shows Survival Benefits in Confirmatory AML Study in China, Other Regions: Astellas
March 31, 2021
- With Promotion Halt Lifted, Nichi-Iko Says to Launch Lyrica OD Generics on April 7
March 30, 2021
- Kyowa Kirin Grants All Worldwide Rights for Anti-LIGHT Antibody to Aevi
March 30, 2021
- Ohara Files Methotrexate Antidote in Japan
March 30, 2021
- Xtandi Gets EU Panel Backing for HSPC: Astellas
March 30, 2021
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…